The changes made in this framework have significant implications, both positive and negative, for all health technology innovators facing the prospect of an evaluation.
TORONTO (PRWEB) March 09, 2020
The Boston-based Institute for Clinical and Economic Review (ICER), an independent research organization that conducts health technology assessments to examine the clinical and economic value of prescription drugs, medical devices, diagnostic tests and other health care and health care delivery innovations, announced on November 13, 2019, that they are considering selecting two or more non-drug topics for assessment in 2020. The list for potential evaluation topics ranges from lenses for cataracts to electronic applications for managing anxiety and depression. These evaluations will be an extension of ICER’s current work on prescription drugs as they work to adapt their experience in decision modeling for pharmaceutical products to models for devices, diagnostics, digital health, procedures, health programs and more.
ICER’s research on non-drug assessments will have substantial implications for device, diagnostic and digital therapeutic innovators, as their new paradigm will allow for comparison of not only drugs against each other (or the natural history of disease) but also a comparison of products from different classifications within the life sciences. For example, the ICER proposed evaluation list of topics also includes a potential comparison of devices for atrial fibrillation compared to the oral anticoagulant, dabigatran.
In addition to this broader evaluation scope, ICER recently undertook their bi-annual value framework update, with the final details released on January 31, 2020. The changes made in this framework have significant implications, both positive and negative, for all health technology innovators facing the prospect of an evaluation. Understanding the updated framework and ways to work within ICER’s established processes is essential for success in ensuring that appropriate pre-evaluation research is undertaken, enabling the sponsor to provide cohesive and compelling input during the evaluation process.
The experts from Boston Healthcare Associates regularly leverage their expertise in health economics and outcomes research to assist clients with health economic strategy, including planning for potential ICER evaluation (or assessment). In this webinar, participants will learn about the updated 2020 value framework, how ICER’s new evaluations may impact your technologies, and how to best prepare for and participate in the evaluation process.
Join Jordan Hinahara, Senior Manager, Boston Healthcare Associates and Thomas F. Goss, Senior Vice President, Boston Healthcare Associates in a live webinar on Wednesday, March 25, 2020 at 11am EDT (NA) (3pm GMT/UK).
For more information or to register for this event, visit How Biopharma & MedTech Companies Can Demonstrate Value Under Recent ICER Updates.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.